130 related articles for article (PubMed ID: 8607177)
1. Combined in vitro and in vivo T lymphocyte depletion for the control of graft-versus-host disease following haploidentical marrow transplant.
Henslee-Downey PJ; Parrish RS; MacDonald JS; Romond EH; Marciniak E; Coffey C; Ciocci G; Thompson JS
Transplantation; 1996 Mar; 61(5):738-45. PubMed ID: 8607177
[TBL] [Abstract][Full Text] [Related]
2. XomaZyme-CD5 immunotoxin in conjunction with partial T cell depletion for prevention of graft rejection and graft-versus-host disease after bone marrow transplantation from matched unrelated donors.
Koehler M; Hurwitz CA; Krance RA; Coustan-Smith E; Williams LL; Santana V; Ribeiro RC; Brenner MK; Heslop HE
Bone Marrow Transplant; 1994 May; 13(5):571-5. PubMed ID: 7519937
[TBL] [Abstract][Full Text] [Related]
3. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
[TBL] [Abstract][Full Text] [Related]
4. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors.
Soiffer RJ; Mauch P; Fairclough D; Alyea E; Anderson K; Fisher D; Freedman A; Bartlett-Pandite L; Robertson M; Schlossman R; Gollob J; Marcus K; Murray C; Kuhlman C; Freeman A; Nadler L; Ritz J
Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736
[TBL] [Abstract][Full Text] [Related]
5. Prevention of graft-versus-host disease with anti-CD5 ricin A chain immunotoxin after CD3-depleted HLA-nonidentical marrow transplantation in pediatric leukemia patients.
Przepiorka D; Chan KW; Champlin RE; Culbert SJ; Petropoulos D; Ippoliti C; Khouri I; Huh YO; Vreisendorp H; Deisseroth AB
Bone Marrow Transplant; 1995 Dec; 16(6):737-41. PubMed ID: 8750262
[TBL] [Abstract][Full Text] [Related]
6. Graft-versus-host disease prevention in allogeneic bone marrow transplantation from histocompatible siblings. A pilot study using immunotoxins for T cell depletion of donor bone marrow.
Filipovich AH; Vallera DA; Youle RJ; Haake R; Blazar BR; Arthur D; Neville DM; Ramsay NK; McGlave P; Kersey JH
Transplantation; 1987 Jul; 44(1):62-9. PubMed ID: 3299923
[TBL] [Abstract][Full Text] [Related]
7. Anti-pan T lymphocyte ricin A chain immunotoxin (H65-RTA) and methylprednisolone for acute GVHD prophylaxis following allogeneic BMT from HLA-identical sibling donors.
Krance R; Heslop HE; Mahmoud H; Ribeiro R; Douglass E; Hurwitz C; Santana V; Kun L; Horowitz MM; Brenner MK
Bone Marrow Transplant; 1993 Jan; 11(1):33-6. PubMed ID: 8431709
[TBL] [Abstract][Full Text] [Related]
8. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease.
Martin PJ; Hansen JA; Torok-Storb B; Moretti L; Press O; Storb R; Thomas ED; Weiden PL; Vitetta ES
Bone Marrow Transplant; 1988 Sep; 3(5):437-44. PubMed ID: 2973360
[TBL] [Abstract][Full Text] [Related]
9. Toxicity and efficacy of anti-T-cell ricin toxin A chain immunotoxins in a murine model of established graft-versus-host disease induced across the major histocompatibility barrier.
Vallera DA; Carroll SF; Snover DC; Carlson GJ; Blazar BR
Blood; 1991 Jan; 77(1):182-94. PubMed ID: 1984794
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.
Martin PJ; Nelson BJ; Appelbaum FR; Anasetti C; Deeg HJ; Hansen JA; McDonald GB; Nash RA; Sullivan KM; Witherspoon RP; Scannon PJ; Friedmann N; Storb R
Blood; 1996 Aug; 88(3):824-30. PubMed ID: 8704237
[TBL] [Abstract][Full Text] [Related]
11. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts.
Henslee PJ; Byers VS; Jennings CD; Marciniak E; Thompson JS; Macdonald JS; Romond EH; Messino MJ; Scannon PJ
Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413
[No Abstract] [Full Text] [Related]
12. Therapy for ongoing graft-versus-host disease induced across the major or minor histocompatibility barrier in mice with anti-CD3F(ab')2-ricin toxin A chain immunotoxin.
Vallera DA; Taylor PA; Panoskaltsis-Mortari A; Blazar BR
Blood; 1995 Dec; 86(11):4367-75. PubMed ID: 7492798
[TBL] [Abstract][Full Text] [Related]
13. Low dose T-cell lymphocyte infusion combined with marrow T-cell depletion as prophylaxis of acute graft vs host disease for HLA identical sibling bone marrow transplantation.
Cahn JY; Deconinck E; Tiberghien P; Brion A; Racadot E; Deschaseaux M; Angonin R; Voillat L; Vuillier J; Fontan J; Morel P; Cordonnier JM; Comparot S; Woronoff-Lemsi MC; Hervé P
Hematol Cell Ther; 1999 Apr; 41(2):31-7. PubMed ID: 10344550
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation.
Przepiorka D; LeMaistre CF; Huh YO; Luna M; Saria EA; Brown CT; Champlin RE
Ther Immunol; 1994 Apr; 1(2):77-82. PubMed ID: 7584486
[TBL] [Abstract][Full Text] [Related]
15. Use of an anti-pan T-lymphocyte ricin a chain immunotoxin in steroid-resistant acute graft-versus-host disease.
Byers VS; Henslee PJ; Kernan NA; Blazar BR; Gingrich R; Phillips GL; LeMaistre CF; Gilliland G; Antin JH; Martin P
Blood; 1990 Apr; 75(7):1426-32. PubMed ID: 2180494
[TBL] [Abstract][Full Text] [Related]
16. T cell depletion with anti-CD5 immunotoxin in histocompatible bone marrow transplantation. The correlation between residual CD5 negative T cells and subsequent graft-versus-host disease.
Filipovich AH; Vallera D; McGlave P; Polich D; Gajl-Peczalska K; Haake R; Lasky L; Blazar B; Ramsay NK; Kersey J
Transplantation; 1990 Sep; 50(3):410-5. PubMed ID: 1698319
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival in advanced chronic myelogenous leukemia following bone marrow transplantation from haploidentical related donors.
Bishop MR; Henslee-Downey PJ; Anderson JR; Romond EH; Marciniak E; Yankey R; Reeves M; Thompson JS
Bone Marrow Transplant; 1996 Oct; 18(4):747-53. PubMed ID: 8899190
[TBL] [Abstract][Full Text] [Related]
18. Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion.
Keever-Taylor CA; Bredeson C; Loberiza FR; Casper JT; Lawton C; Rizzo D; Burns WH; Margolis DA; Vesole DH; Horowitz M; Zhang MJ; Juckett M; Drobyski WR
Biol Blood Marrow Transplant; 2001; 7(11):620-30. PubMed ID: 11760150
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients.
Mehta J; Singhal S; Gee AP; Chiang KY; Godder K; Rhee Fv Fv; DeRienzo S; O'Neal W; Lamb L; Henslee-Downey PJ
Bone Marrow Transplant; 2004 Feb; 33(4):389-96. PubMed ID: 14716338
[TBL] [Abstract][Full Text] [Related]
20. Prophylaxis for acute graft-versus-host disease following unrelated donor bone marrow transplantation.
Phillips GL; Nevill TJ; Spinelli JJ; Nantel SH; Klingemann HG; Barnett MJ; Shepherd JD; Chan KW; Meharchand JM; Sutherland HJ
Bone Marrow Transplant; 1995 Feb; 15(2):213-9. PubMed ID: 7539667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
